logo

Ligand Pharmaceuticals Inc (LGND)



Trade LGND now with
  Date
  Headline
3/30/2018 9:16:40 AM Ligand Reaches Agreement With VenBio To Make Worldwide OmniAb Platform License Accessible To Portfolio Companies
3/6/2018 4:04:00 PM Ligand Licenses Glucagon Receptor Antagonist Program To Roivant Sciences
2/21/2018 4:03:17 PM Ligand Pharma Q4 Loss/share $0.33 Vs. Loss $0.15 Year Ago
1/22/2018 9:01:49 AM Ligand Enters Into Worldwide OmniAb Platform License Agreement With Ferring Pharma
1/11/2018 9:02:50 AM Ligand Enters Worldwide OmniAb Platform License Agreement With Glenmark Pharmaceuticals
1/3/2018 9:05:49 AM Ligand Says Now Expects FY17 Total Revenue Of About $140 Mln, Adj. EPS Of $3.13-$3.16
11/3/2016 4:06:43 PM Ligand Pharmaceuticals Inc (LGND) Has Lowered Its FY16 Revenue Estimate To $110 - $114 Mln From $115 - $119 Mln
11/3/2016 4:06:04 PM Ligand Pharmaceuticals Inc (LGND) Has Lowered Its FY16 EPS Estimate To 3.37 - 3.44 From 3.41 - 3.46
8/5/2016 12:47:29 PM Deutsche Bank Lowers Ligand Pharmaceuticals Inc (LGND) To Sell From Hold With $110 Up From $104 Price Target
11/9/2015 4:14:13 PM Ligand Pharmaceuticals Inc (LGND) Has Lowered Its 2015 EPS Estimate To 3.34 - 3.37 From 3.45 - 3.50
11/9/2015 4:13:37 PM Ligand Pharmaceuticals Inc (LGND) Has Lowered Its 2015 Revenue Estimate To $75 - $76 Mln From $81 - $83 Mln
8/4/2015 4:08:24 PM Ligand Pharmaceuticals Inc (LGND) Has Raised Its 2015 EPS Estimate To 3.45 - 3.50 From 2.14 - 2.18
6/15/2015 12:44:45 PM Deutsche Bank Cuts Ligand Pharmaceuticals Inc (LGND) To Hold From Buy With $94 Price Target